A review of cellular and acellular matrix products: Indications, techniques, and outcomes

Olivia B. Hughes, Adele Rakosi, Flor MacQuhae, Ingrid Herskovitz, Joshua D. Fox, Robert Kirsner

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Background: Wound healing is a dynamic process whereby cells, growth factors (GFs), and the extracellular matrix (ECM) interact to restore the architecture of damaged tissue. Chronic wounds can be diffcult to treat due to the increased presence of inflammatory cells that degrade the ECM, GF, and cells necessary for wound healing to occur. Cellular and acellular matrix products can be used in the management of a variety of chronic wounds including venous, diabetic, and pressure ulcers and other conditions such as burns, epidermolysis bullosa, pyoderma gangrenosum, and surgical wounds. These matrices provide cells, GF, and other key elements that act as a scaffold and promote reepithelialization and revascularization of the wound bed. Methods: This article focuses on cellular and acellular matrix products that have been well-studied clinically with positive results in randomized clinical trials and widely available matrices for chronic nonhealing wounds. We present trial results as well as their indications, techniques, and outcomes. Results: There are a variety of matrix products available on the market. Some of these products are used to treat chronic wounds, for example, diabetic foot ulcers, venous leg ulcers, pyoderma gangrenosum, and pressure ulcers. In this review, we found that wounds of different etiologies have been treated with a variety of matrices, with successful outcomes compared with standard wound care. Conclusions: Both cellular and acellular matrix products are useful in the management of a variety of chronic wounds. These matrices provide cells, GF, and other key elements that promote reepithelialization and revascularization of the wound bed while preventing degradation of the ECM. The treatment of chronic wounds with matrix products in combination with standard wound care has been proven to aid in wound healing when added to standard of care.

Original languageEnglish (US)
Pages (from-to)138S-147S
JournalPlastic and Reconstructive Surgery
Volume138
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Wounds and Injuries
Intercellular Signaling Peptides and Proteins
Wound Healing
Pyoderma Gangrenosum
Extracellular Matrix
Varicose Ulcer
Pressure Ulcer
Epidermolysis Bullosa
Leg Ulcer
Diabetic Foot
Venous Pressure
Standard of Care
Burns
Randomized Controlled Trials

ASJC Scopus subject areas

  • Surgery

Cite this

A review of cellular and acellular matrix products : Indications, techniques, and outcomes. / Hughes, Olivia B.; Rakosi, Adele; MacQuhae, Flor; Herskovitz, Ingrid; Fox, Joshua D.; Kirsner, Robert.

In: Plastic and Reconstructive Surgery, Vol. 138, No. 3, 2016, p. 138S-147S.

Research output: Contribution to journalReview article

Hughes, Olivia B. ; Rakosi, Adele ; MacQuhae, Flor ; Herskovitz, Ingrid ; Fox, Joshua D. ; Kirsner, Robert. / A review of cellular and acellular matrix products : Indications, techniques, and outcomes. In: Plastic and Reconstructive Surgery. 2016 ; Vol. 138, No. 3. pp. 138S-147S.
@article{045d96432b9c4c71b9c895e5b8ffe8b0,
title = "A review of cellular and acellular matrix products: Indications, techniques, and outcomes",
abstract = "Background: Wound healing is a dynamic process whereby cells, growth factors (GFs), and the extracellular matrix (ECM) interact to restore the architecture of damaged tissue. Chronic wounds can be diffcult to treat due to the increased presence of inflammatory cells that degrade the ECM, GF, and cells necessary for wound healing to occur. Cellular and acellular matrix products can be used in the management of a variety of chronic wounds including venous, diabetic, and pressure ulcers and other conditions such as burns, epidermolysis bullosa, pyoderma gangrenosum, and surgical wounds. These matrices provide cells, GF, and other key elements that act as a scaffold and promote reepithelialization and revascularization of the wound bed. Methods: This article focuses on cellular and acellular matrix products that have been well-studied clinically with positive results in randomized clinical trials and widely available matrices for chronic nonhealing wounds. We present trial results as well as their indications, techniques, and outcomes. Results: There are a variety of matrix products available on the market. Some of these products are used to treat chronic wounds, for example, diabetic foot ulcers, venous leg ulcers, pyoderma gangrenosum, and pressure ulcers. In this review, we found that wounds of different etiologies have been treated with a variety of matrices, with successful outcomes compared with standard wound care. Conclusions: Both cellular and acellular matrix products are useful in the management of a variety of chronic wounds. These matrices provide cells, GF, and other key elements that promote reepithelialization and revascularization of the wound bed while preventing degradation of the ECM. The treatment of chronic wounds with matrix products in combination with standard wound care has been proven to aid in wound healing when added to standard of care.",
author = "Hughes, {Olivia B.} and Adele Rakosi and Flor MacQuhae and Ingrid Herskovitz and Fox, {Joshua D.} and Robert Kirsner",
year = "2016",
doi = "10.1097/PRS.0000000000002643",
language = "English (US)",
volume = "138",
pages = "138S--147S",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A review of cellular and acellular matrix products

T2 - Indications, techniques, and outcomes

AU - Hughes, Olivia B.

AU - Rakosi, Adele

AU - MacQuhae, Flor

AU - Herskovitz, Ingrid

AU - Fox, Joshua D.

AU - Kirsner, Robert

PY - 2016

Y1 - 2016

N2 - Background: Wound healing is a dynamic process whereby cells, growth factors (GFs), and the extracellular matrix (ECM) interact to restore the architecture of damaged tissue. Chronic wounds can be diffcult to treat due to the increased presence of inflammatory cells that degrade the ECM, GF, and cells necessary for wound healing to occur. Cellular and acellular matrix products can be used in the management of a variety of chronic wounds including venous, diabetic, and pressure ulcers and other conditions such as burns, epidermolysis bullosa, pyoderma gangrenosum, and surgical wounds. These matrices provide cells, GF, and other key elements that act as a scaffold and promote reepithelialization and revascularization of the wound bed. Methods: This article focuses on cellular and acellular matrix products that have been well-studied clinically with positive results in randomized clinical trials and widely available matrices for chronic nonhealing wounds. We present trial results as well as their indications, techniques, and outcomes. Results: There are a variety of matrix products available on the market. Some of these products are used to treat chronic wounds, for example, diabetic foot ulcers, venous leg ulcers, pyoderma gangrenosum, and pressure ulcers. In this review, we found that wounds of different etiologies have been treated with a variety of matrices, with successful outcomes compared with standard wound care. Conclusions: Both cellular and acellular matrix products are useful in the management of a variety of chronic wounds. These matrices provide cells, GF, and other key elements that promote reepithelialization and revascularization of the wound bed while preventing degradation of the ECM. The treatment of chronic wounds with matrix products in combination with standard wound care has been proven to aid in wound healing when added to standard of care.

AB - Background: Wound healing is a dynamic process whereby cells, growth factors (GFs), and the extracellular matrix (ECM) interact to restore the architecture of damaged tissue. Chronic wounds can be diffcult to treat due to the increased presence of inflammatory cells that degrade the ECM, GF, and cells necessary for wound healing to occur. Cellular and acellular matrix products can be used in the management of a variety of chronic wounds including venous, diabetic, and pressure ulcers and other conditions such as burns, epidermolysis bullosa, pyoderma gangrenosum, and surgical wounds. These matrices provide cells, GF, and other key elements that act as a scaffold and promote reepithelialization and revascularization of the wound bed. Methods: This article focuses on cellular and acellular matrix products that have been well-studied clinically with positive results in randomized clinical trials and widely available matrices for chronic nonhealing wounds. We present trial results as well as their indications, techniques, and outcomes. Results: There are a variety of matrix products available on the market. Some of these products are used to treat chronic wounds, for example, diabetic foot ulcers, venous leg ulcers, pyoderma gangrenosum, and pressure ulcers. In this review, we found that wounds of different etiologies have been treated with a variety of matrices, with successful outcomes compared with standard wound care. Conclusions: Both cellular and acellular matrix products are useful in the management of a variety of chronic wounds. These matrices provide cells, GF, and other key elements that promote reepithelialization and revascularization of the wound bed while preventing degradation of the ECM. The treatment of chronic wounds with matrix products in combination with standard wound care has been proven to aid in wound healing when added to standard of care.

UR - http://www.scopus.com/inward/record.url?scp=84988462551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988462551&partnerID=8YFLogxK

U2 - 10.1097/PRS.0000000000002643

DO - 10.1097/PRS.0000000000002643

M3 - Review article

C2 - 27556754

AN - SCOPUS:84988462551

VL - 138

SP - 138S-147S

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 3

ER -